Drug Trial Radar · NCT05200442
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
53
Planned (sponsor's estimate)
Start
Aug 22, 2022
Primary completion
May 1, 2027
Study completion May 1, 2027
Sponsor
- Lead sponsor
- University of ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Verastem, Inc.
- First posted
- Jan 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatment or individuals who cannot take/tolerate previous treatments. If you choose to participate, your time in this research will last up to 24 months.
Conditions
- Colorectal Cancer
- Colorectal Adenocarcinoma
- Colorectal Cancer Metastatic
- Advanced Colorectal Carcinoma
- Advanced Colorectal Adenocarcinoma
Interventions
VS-6766/avutometinibDrug
An oral anti-cancer medication.
CetuximabDrug
A chemotherapy drug used to treat head, neck and colorectal cancer.
Pill DiaryOther
A diary where participants in phase 2 of study will log their medications and times they are taken on study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I Primary Objective: Maximum Tolerated Dose (MTD) of VS-6766 combined with CetuximabTime frame: 2 years
- Phase 2 Primary Objective: Objective Response Rate of Participants Who Take Phase I /MTD Dose of VS-6766 combined with CetuximabTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Chicago Medical Center
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.